Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time.
Poxel's innovative pipeline of first-in-class products with disease-modifying mechanisms of action offers the potential for safer and more effective therapies for metabolic diseases. Our lead compound, Imeglimin, successfully completed Phase 3 development in Japan. A Japanese new drug application (J-NDA) is under review by the Pharmaceuticals and Medical Devices Agency (PMDA) to request approval for the manufacturing and marketing of Imeglimin for the treatment of type 2 diabetes and a product launch is anticipated in the second half of 2021. Imeglimin is also Phase 3-ready in the US and Europe. PXL770 has completed Phase 1 and entered a Phase 2a proof-of-concept program for the treatment of NASH in April 2019. PXL065 is in a single Phase 2 trial for the treatment of NASH. Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases.
Inception date: 2009
Stock market: Euronext Paris - Compartment B
ISIN code: FR0012432516
Immeuble Le Sunway
259-261 Avenue Jean Jaurès
Poxel also has subsidiaries in Boston, Massachussets, United States, and in Tokyo, Japan